MedPath

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

Phase 2
Completed
Conditions
Hepatitis C
Interventions
Drug: Pegylated interferon alfa 2a
Registration Number
NCT00535847
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Brief Summary

To provide access to a telaprevir-based treatment to subjects of the Control Group of Study VX06-950-106 (NCT00420784), VX05-950-104 (NCT00336479), and VX05-950-104EU (NCT00372385) who stopped treatment due to inadequate response to treatment. Safety, tolerability, and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) levels will be collected.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
117
Inclusion Criteria
  • Enrolled in the control arm of Study VX06-950-106 (NCT00420784), VX05-950-104 (NCT00336479) or VX05-950-104EU (NCT00372385)
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 WeekTelaprevirTelaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks.
Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 WeekPegylated interferon alfa 2aTelaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks.
Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 WeekRibavirinTelaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 24 weeks.
Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 WeekPegylated interferon alfa 2aTelaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 24 weeks.
OtherPegylated interferon alfa 2aSubjects received telaprevir 750 mg tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, discontinued treatment before Week 12 in this study (VX06-950-107 \[NCT00535847\]) and had a partial response, viral breakthrough, or relapse in the parent study (VX05-950-104 \[NCT00336479\], VX05-950-104EU \[NCT00372385\] or VX06-950-106 \[NCT00420784\]) were included in "Other" reporting group.
Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 WeekTelaprevirTelaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 24 weeks.
Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 WeekRibavirinTelaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks.
OtherTelaprevirSubjects received telaprevir 750 mg tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, discontinued treatment before Week 12 in this study (VX06-950-107 \[NCT00535847\]) and had a partial response, viral breakthrough, or relapse in the parent study (VX05-950-104 \[NCT00336479\], VX05-950-104EU \[NCT00372385\] or VX06-950-106 \[NCT00420784\]) were included in "Other" reporting group.
OtherRibavirinSubjects received telaprevir 750 mg tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, discontinued treatment before Week 12 in this study (VX06-950-107 \[NCT00535847\]) and had a partial response, viral breakthrough, or relapse in the parent study (VX05-950-104 \[NCT00336479\], VX05-950-104EU \[NCT00372385\] or VX06-950-106 \[NCT00420784\]) were included in "Other" reporting group.
Primary Outcome Measures
NameTimeMethod
Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Treatment24 weeks after the completion of treatment (up to Week 72)

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).

Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)Baseline through Week 48

AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents (including placebo, if applicable) administered during the course of the study.

Secondary Outcome Measures
NameTimeMethod
Percentage of Prior Relapsers With Undetectable HCV RNA24 weeks after the completion of treatment (up to Week 72)

Prior relapsers: subjects who had undetectable HCV RNA at the end of treatment in parent study but reverted to detectable levels of HCV RNA after stopping treatment in parent study were categorized as prior relapsers. Percentage of prior relapsers with undetectable HCV RNA 24 weeks after the completion of treatment in this study were presented. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).

Percentage of Subjects With Undetectable HCV RNA at Week 48 After Completion of Treatment Among Subjects Who Completed Assigned Treatment48 weeks after completion of treatment (up to Week 96)

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).

Percentage of Subjects With End of Treatment ResponseEnd of treatment (up to Week 48)

Subjects were considered to have an end of treatment response if they completed the assigned treatment regimen and had undetectable HCV RNA at end of treatment or prematurely discontinued the assigned treatment regimen and had undetectable HCV RNA at the time of discontinuation. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).

Cross Tabulation of Extended Rapid Viral Response (eRVR) and Sustained Viral Response (SVR) in With Prior ResponseBaseline up to Week 72

Cross tabulation of number of subjects with eRVR/SVR status in present study was presented with respect to prior response status of subjects in parent studies. eRVR=undetectable HCV RNA at Week 4 and Week 12, SVR=undetectable HCV RNA at end of treatment (EOT) and at 24 weeks after last dose of study treatment without any confirmed detectable HCV RNA in between. Prior response=subjects were categorized into following categories based on their viral response in the parent study: Null Response (less than \[\<\] 1-log10 decrease in HCV RNA at Week 4 or \<2-log10 decrease in HCV RNA at Week 12), Partial Response (greater than \[\>\] 2-log10 decrease in HCV RNA at Week 12, but detectable HCV RNA at Week 24), Viral Breakthrough (detectable HCV RNA during treatment after achieving undetectable HCV RNA), Relapse (undetectable HCV RNA at EOT but detectable HCV RNA during viral follow-up). Plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay; lower limit of detection=10 IU/mL.

Trial Locations

Locations (41)

Atlanta Gastroenterology Associates

🇺🇸

Atlanta, Georgia, United States

South Denver Gastroenterology

🇺🇸

Englewood, Colorado, United States

University of Florida

🇺🇸

Gainesville, Florida, United States

Borland-Groover Clinic

🇺🇸

Jacksonville, Florida, United States

Mayo Clinic Jacksonville

🇺🇸

Jacksonville, Florida, United States

Digestive and Liver Disease Clinic

🇺🇸

Baton Rouge, Louisiana, United States

University of Chicago

🇺🇸

Chicago, Illinois, United States

Virology Treatment Center, Maine Medical Center

🇺🇸

Portland, Maine, United States

University of Massachusetts Memorial Medical Center

🇺🇸

Worcester, Massachusetts, United States

Beth Israel Deaconess Medical Center

🇺🇸

Boston, Massachusetts, United States

St Louis University

🇺🇸

St Louis, Missouri, United States

North Shore University Hospital

🇺🇸

Manhasset, New York, United States

Penn State Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Columbia Gastroenterology Associates, PA

🇺🇸

Columbia, South Carolina, United States

Liver Institute at Methodist Dallas

🇺🇸

Dallas, Texas, United States

Memphis Gastroenterology Group

🇺🇸

Germantown, Tennessee, United States

University of Virginia Health Systems

🇺🇸

Charlottesville, Virginia, United States

McGuire DVAMC

🇺🇸

Richmond, Virginia, United States

Metropolitan Research

🇺🇸

Fairfax, Virginia, United States

University of Calgary Medical Clinic

🇨🇦

Calgary, Alberta, Canada

University of Alberta

🇨🇦

Edmonton, Alberta, Canada

University of British Columbia Vancouver General Hospital

🇨🇦

Vancouver, British Columbia, Canada

Hospital Henri Mondor

🇫🇷

Creteil, France

Universitatsklinikum Bonn

🇩🇪

Bonn, Germany

University of Cologne

🇩🇪

Cologne, Germany

Uniklinik Duesseldorf

🇩🇪

Dusseldorf, Germany

Academic Medical Center

🇳🇱

Amsterdam, Netherlands

Leiden University Medical Center

🇳🇱

Leiden, Netherlands

Erasmus MC Medical Center

🇳🇱

Rotterdam, Netherlands

Fundacion de Investigation de Diego

🇵🇷

Santurce, Puerto Rico

Kaiser Permanente Internal Medicine

🇺🇸

San Diego, California, United States

University of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

University of Colorado Health Sciences Center

🇺🇸

Denver, Colorado, United States

University of Miami Center for Liver Diseases

🇺🇸

Miami, Florida, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

The Nebraska Medical Center

🇺🇸

Omaha, Nebraska, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

Alamo Medical Research

🇺🇸

San Antonio, Texas, United States

Johns Hopkins University

🇺🇸

Baltimore, Maryland, United States

University of New Mexico

🇺🇸

Albuquerque, New Mexico, United States

© Copyright 2025. All Rights Reserved by MedPath